Aripiprazole augmentation treatment in treatment resistant bipolar depression: two patient reports.
نویسندگان
چکیده
It is known that in patients with bipolar disorder, depressive episodes last longer than mixed or manic/hypomanic episodes and there are reports detailing the difficulties confronted in its treatment. The concept of treatment resistant depression in bipolar disorder has not been as well described as that in treatment resistant unipolar depression. Here we present two patients with treatment resistant bipolar depression. The first patient in our study is a 51 year old woman whose diagnoses were bipolar disorder, depressive episode and multiple sclerosis (in remission with interferon treatment) at the time of augmentation with aripiprazole. The second patient is a 43 year old woman with bipolar disorder, depressive disorder without any comorbid illness at the time of augmentation with aripiprazole. Aripiprazole was administered variably between 20-30mg/daily based on tolerability and efficacy. In both cases, depression was assessed using the Hamilton Depression Rating scale (HDRS). Both patients responded to aripiprazole augmentation treatment. The effect of aripiprazole on bipolar depression needs to be further evaluated in double blind controlled studies. However, augmentation with aripiprazole in bipolar patients may be a future routine treatment for treatment resistant bipolar depression. In this report, treatment of refractory bipolar depression and the efficacy of aripiprazole augmentation treatment in bipolar depression are discussed through two patients in depressive episode who remitted with aripiprazole augmentation.
منابع مشابه
A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
BACKGROUND Several studies have evaluated the efficacy and tolerability of aripiprazole for augmentation of antidepressant therapy for treatment-resistant depression (TRD). Here, we investigated the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and bipolar disorder and the clinical predictors of treatment efficacy in a Japanese population. METHODS Eigh...
متن کاملA Case of Treatment Resistant Depression and Alcohol Abuse in a Person with Mental Retardation: Response to Aripiprazole and Fluvoxamine Therapy upon Consideration of a Bipolar Diathesis after Repetitive Failure to Respond to Multiple Antidepressant Trials
Mental Retardation (MR) is a developmental disability characterized by impairments in adaptive daily life skills and difficulties in social and interpersonal functioning. Since multiple causes may contribute to MR, associated clinical pictures may vary accordingly. Nevertheless, when psychiatric disorders as Treatment Resistant Depression (TRD) and/or alcohol abuse co-exist, their proper detect...
متن کاملAripiprazole augmentation in managing comorbid obsessive–compulsive disorder and bipolar disorder: a case with suicidal attempts
Comorbid obsessive-compulsive disorder (OCD) and bipolar disorder (BD) have long been an intractable problem in clinical practice. The increased risk of manic/hypomanic switch hinders the use of antidepressants for managing coexisting OCD symptoms in BD patients. We herein present a case of a patient with BD-OCD comorbidity, who was successfully treated with mood stabilizers and aripiprazole au...
متن کاملAugmentation of Clozapine with Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: A Pilot Study
AIM To evaluate the efficacy and safety of the augmentation of clozapine with aripiprazole in patients with treatment-resistant schizoaffective and psychotic bipolar disorders in a retrospective manner. Pharmacodynamic and pharmacokinetic interactions between the two drugs were also investigated. PATIENTS Three men and 4 women (median age 36 and 40 years, respectively) who had mean scores at ...
متن کاملHypomania associated with adjunctive low-dose aripiprazole: two case reports and a brief review of the literature.
Aripiprazole is one of the newest atypical antipsychotic medications. It has proven to be effective in the treatment of schizophrenia (Hasan et al. 2012, 2013), bipolar manic and mixed states (Yatham et al. 2013, Grunze et al. 2013) and, recently, as an adjunctive agent in patients with treatment-resistant major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) (Wright et al. 20...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Turk psikiyatri dergisi = Turkish journal of psychiatry
دوره 22 4 شماره
صفحات -
تاریخ انتشار 2011